The emergence of artemisinin partial resistance in Africa: how do we respond?
(2024) The Lancet Infectious Diseases — Vol. 24, n° 9, p. e591-e600 (2024)
Files
2024_Rosenthal_Lancet_Infect_Dis.pdf
Restricted Access - Adobe PDF
- 613.2 KB
Details
- Authors
- Abstract
- Malaria remains one of the most important infectious diseases in the world, with the greatest burden in sub-Saharan Africa, primarily from Plasmodium falciparum infection. The treatment and control of malaria is challenged by resistance to most available drugs, but partial resistance to artemisinins (ART-R), the most important class for the treatment of malaria, was until recently confined to southeast Asia. This situation has changed, with the emergence of ART-R in multiple countries in eastern Africa. ART-R is mediated primarily by single point mutations in the P falciparum kelch13 protein, with several mutations present in African parasites that are now validated resistance mediators based on clinical and laboratory criteria. Major priorities at present are the expansion of genomic surveillance for ART-R mutations across the continent, more frequent testing of the efficacies of artemisinin-based regimens against uncomplicated and severe malaria in trials, more regular assessment of ex-vivo antimalarial drug susceptibilities, consideration of changes in treatment policy to deter the spread of ART-R, and accelerated development of new antimalarial regimens to overcome the impacts of ART-R. The emergence of ART-R in Africa is an urgent concern, and it is essential that we increase efforts to characterise its spread and mitigate its impact.
- Affiliations
Citations
Rosenthal, P. J., Asua, V., Bailey, J. A., Conrad, M. D., Ishengoma, D. S., Kamya, M. R., Rasmussen, C., Tadesse, F. G., Uwimana, A., & Fidock, D. A. (2024). The emergence of artemisinin partial resistance in Africa: how do we respond? The Lancet Infectious Diseases, 24(9), e591-e600. https://doi.org/10.1016/S1473-3099(24)00141-5 (Original work published 2024)